Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01834300
Recruitment Status : Unknown
Verified September 2014 by Daniel Cuthbertson, University of Liverpool.
Recruitment status was:  Active, not recruiting
First Posted : April 17, 2013
Last Update Posted : September 17, 2014
Sponsor:
Collaborators:
Royal Liverpool University Hospital
University of Surrey
Imperial College London
Royal Surrey County Hospital
Information provided by (Responsible Party):
Daniel Cuthbertson, University of Liverpool

Brief Summary:
This project examines the effects of a 4 month structured exercise intervention program in patients with non-alcoholic fatty liver disease (NAFLD). We will examine changes in total and depot-specific (i.e.in different tissues, liver, muscle and pancreas)fat. We will correlate these with measurements of the insulin from the liver. The hypothesis is that by reducing fat in these specific depots we can reduce insulin resistance and prevent progression to diabetes.

Condition or disease Intervention/treatment Phase
Non Alcoholic Fatty Liver Disease Behavioral: Unsupervised exercise training Behavioral: Supervised exercise training Not Applicable

Detailed Description:
  1. Exercise program: We are asking people to take part in a supervised exercise program for 4 months. This involves on average a weekly supervised exercise bout plus other unsupervised exercise bouts at home. We will ensure participants are physically able to embark on this by taking their medical history, physical examination and validated questionnaire (PARQ). This program is for the benefit on the patients' long term health.
  2. MR imaging to assess fat: occassionally these may pick up anomalies which require further investigation. A radiologist will screen the abdominal images and GP will be informed on anything requiring further investigation.

    No radiation is received during MR imaging.

  3. Physiological studies: Patients will be asked to attend for 2 non-consecutive days before and after the exercise intervention. Regular blood samples will be required as apart of these investigations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, β-cell Function and Triglyceride Kinetics in Patients With Non-alcoholic Fatty Liver Disease (NAFLD).
Study Start Date : February 2009
Actual Primary Completion Date : April 2013
Estimated Study Completion Date : June 2015


Arm Intervention/treatment
Experimental: Control
Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
Behavioral: Unsupervised exercise training
The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.

Experimental: lifestyle counseling and exercise
Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
Behavioral: Supervised exercise training
Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.




Primary Outcome Measures :
  1. Reduction in liver and muscle fat [ Time Frame: 4 months ]
    Tissue triglyceride content, or steatosis, will be accurately and non-invasively quantified in vivo using localized proton magnetic resonance spectroscopy (1H MRS).


Secondary Outcome Measures :
  1. Changes in liver function tests [ Time Frame: 4 months ]
    Biochemial measurements of the liver enzymes will be measured pre and post intervention period

  2. Changes in lipid profiles [ Time Frame: 4 months ]
    Total cholesterol, triglyceride and high density lipoprotien concentrations in fasting state will be measured pre and post intervention period.

  3. Changes in body weight and anthropometric measurements [ Time Frame: 4 months ]
    Body weight and waist to hip ratio will be measured pre and post intervention period.

  4. Hepatic insulin sensitivity [ Time Frame: 4 months ]
    Half of the study cohort i.e. 30 individuals,15 exercise and 15 controls, will have peripheral and hepatic insulin sensitivity determined using a two-stage hyperinsulinaemic, euglycaemic clamp and use of deuterated glucose (2H2-glucose

  5. VLDL-TG kinetics [ Time Frame: 4 months ]
    The other half of the study cohort i.e. 30 individuals, 15 exercise and 15 controls, will have VLDL1 and VLDL2 TG kinetics determined using 5H2 glycerol bolus.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Sedentary, non smoking, male subjects,
  • Alcohol consumption men <21 units/week,
  • BMI 27-35. (Lean individuals do not suffer from NAFLD, so are not suitable for this study. Conversely, we are restricted to a maximum BMI of 35 due to the size limitations of the MR scanner.)
  • A clinical diagnosis of NAFLD based upon the following criteria: i) exclusion of other causes of liver disease i.e. negative Hepatitis B and C serology, a negative auto-immune profile and normal caeruloplasmin concentrations, ii) Ultrasound appearances suggestive of a fatty, echo-bright liver with no evidence of cirrhosis (in some cases, the diagnosis will have been confirmed histologically after liver biopsy.
  • Being willing to engage and motivated to follow an exercise program.

Exclusion Criteria:

  • Prescription of corticosteroids, amiodarone, tamoxifen, methotrexate (drugs known to cause secondary steatohepatitis) or fibrates. Statin is Ok as long as the patients are on stable therapy for a while, if changed then the patient will be excluded.
  • Alcohol consumption for men 21 units/week.
  • A contraindication to exercise (such as unstable ischaemic heart disease),
  • Type 2 diabetes (type 2 diabetes patients are excluded so that we are examining the involvement of insulin resistance at a reversible stage before β-cell failure has occurred).
  • Patients who are on medications that will interact with GTN (glyceryl trinitrate) will be excluded from the GTN dilatation (endothelial independent NO mediated function) aspect of the study.
  • Individuals who suffer from claustrophobia and have metal implants will be excluded from the MRI aspect of the study.
  • Patients who smoke will also be excluded from the study.
  • Total cholesterol >7

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01834300


Locations
Layout table for location information
United Kingdom
Royal Surrey County Hospital
Guildford, Surrey, United Kingdom, GU16 7UJ
University of Surrey
Guildford, Surrey, United Kingdom, GU27WG
John Moores University
Liverpool, United Kingdom, L3 2ET
University of Liverpool
Liverpool, United Kingdom, L69 3GE
Royal Liverpool University Hospital
Liverpool, United Kingdom, L7 8XP
Liverpool University
Liverpool, United Kingdom, L9 7AL
Imperial College London
London, United Kingdom, W12 0HS
Sponsors and Collaborators
University of Liverpool
Royal Liverpool University Hospital
University of Surrey
Imperial College London
Royal Surrey County Hospital
Investigators
Layout table for investigator information
Study Director: Daniel Cuthbertson, BSc PhD MRCP University of Liverpool
Principal Investigator: Fariba Shojaee-Moradie, BSc PhD University of Surrey

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Daniel Cuthbertson, Senior Lecturer and Honorary Consultant Physician, University of Liverpool
ClinicalTrials.gov Identifier: NCT01834300     History of Changes
Other Study ID Numbers: 09/H1008/1
First Posted: April 17, 2013    Key Record Dates
Last Update Posted: September 17, 2014
Last Verified: September 2014

Keywords provided by Daniel Cuthbertson, University of Liverpool:
Hepatic insulin sensitivity
Muscle insulin sensitivity
B cell function
VLDL1 TG metabolism
VLDL2 TG metabolism

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Insulin Resistance
Digestive System Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs